In a minority of cases it can lead to severe outcomes, including death
Semaglutide is contraindicated in patients with: Personal or family history of medullary thyroid carcinoma (MTC) Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Common Adverse Effects According to clinical trial data, gastrointestinal effects are most frequently reported: nausea, vomiting, diarrhea, constipation, and abdominal discomfort
Gallbladder considerations: Full-dose GLP-1 therapy is associated with increased gallbladder events
Nausea rates in the STEP trials were 44%, substantially higher than Retatrutides 28%
Zhang, K., Hooper, W., Harkness, L., & Ghassemi, A
Hence, we cannot prove that retatrutide directly stimulated the sinus node in the human heart but only present evidence in mouse right atrial preparations for a positive chronotropic effect of retatrutide in a companion paper and in abstract form (Neumann et al